An increase in PD1+CD8+ T cells, which has been shown to contain a pool of systemic tumor-specific T cells,42,43 and PD1+CD4+ T cells was also observed in response to CXCL9/10-DC, with the highest magnitude following combination therapy (Figures 7A and 7B). This evidence concerns the gene CD8A and neoplasm.